MDS Nordion has begun making commercial quantities of rhenium 186 (Re-186) and high-specific-activity lutetium 177 (Lu-177). Demand is growing for these radioisotopes for use in research aimed at developing new cancer therapies. Lu-177, a low-energy beta
MDS Nordion has begun making commercial quantities of rhenium 186 (Re-186) and high-specific-activity lutetium 177 (Lu-177). Demand is growing for these radioisotopes for use in research aimed at developing new cancer therapies. Lu-177, a low-energy beta emitter, shows promise against small tumors. It has a relatively long 6.65-day half-life, which allows more sophisticated procedures to be used for its purification and synthesis. The long half-life also makes Lu-177 easier to combine with biologically active compounds. Re-186 is being investigated for a range of radiotherapeutic applications. It is currently being used for pain palliation from cancerous metastases in bones. Both Lu-177 and Re-186 emit gamma radiation that enables imaging.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.